Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGM - Delayed Quote USD

Longevity Health Holdings, Inc. (XAGEW)

Compare
0.0220
0.0000
(0.00%)
At close: March 13 at 4:00:00 PM EDT
Loading Chart for XAGEW
  • Previous Close 0.0220
  • Open 0.0301
  • Bid --
  • Ask --
  • Day's Range 0.0220 - 0.0220
  • 52 Week Range 0.0220 - 0.0220
  • Volume 10,415
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Longevity Health Holdings, Inc. operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Corporation and changed its name to Longevity Health Holdings, Inc. in March 2025. Longevity Health Holdings, Inc. was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

www.carmellcosmetics.com

9

Full Time Employees

--

Fiscal Year Ends

Recent News: XAGEW

View More

Compare To: XAGEW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: XAGEW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -6.39%

  • Return on Equity (ttm)

    -115.65%

  • Revenue (ttm)

    32.84k

  • Net Income Avi to Common (ttm)

    -9.75M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    3.76M

Research Analysis: XAGEW

View More

Company Insights: XAGEW

Research Reports: XAGEW

View More

People Also Watch